Top 5 Rare Kidney Disease Drug Developers

Published: September 2026

Kidney disorders are known to have a serious impact on the general kidney function, often lowering its ability to filter out waste and fluids from the blood, maintaining blood pressure, hemoglobin levels and electrolyte balance. Kidney disorders can either be short-term (acute kidney injury) or lifelong (chronic). There are several factors which contribute to an increased risk of developing kidney diseases, including genetic causes and underlying metabolic causes (diabetes, high blood pressure, aging and obesity), which when combined with other factors increase the risk of developing kidney diseases. Moreover, the rising incidence and prevalence of rare kidney diseases, with poor outcomes and high cost has led to an increased research activity in this domain.

Despite their relatively low prevalence, rare kidney diseases, such as Immunoglobulin A nephropathy, lupus nephritis, focal segmental glomerulosclerosis, membranous nephropathy and C3 glomerulopathy, are believed to be major types of rare renal diseases. Diagnosis, management and treatment of such rare kidney diseases are complicated, especially when multi-system complications are present. Some of the challenges related to rare kidney diseases include small numbers of affected patients, insufficient model organisms, lack of biomarkers for monitoring disease progression, clinical heterogeneity, health policy constraints and need for complex care.

Rare kidney disorders are known to have a genetic basis that are frequently progressive, disabling and life-threatening. Additionally, the highly heterogeneous nature of rare kidney diseases has been a challenge for the identification of disease specific targets. In order to investigate the new pathophysiological pathways for the identification of human translatable biomarkers and increase the success rate in drug development, various technologies are being integrated, including next generation sequencing, omics analysis and artificial intelligence, with the ability to probe the diseased organ directly

has conducted an exhaustive study on featuring the current market landscape and future opportunity for the for companies engaged in developing rare kidney disease drugs, over a span of next 10 years.

Top Five Rare Kidney Disease Drug Developers

Alexion Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals
Novartis
Roche
Vertex Pharmaceuticals

The figure below highlights the top five rare kidney disease drug developers:

Top Players to Watch Rare Kidney Diseases Market

Interested in exploring all ~95 players engaged in the development of drugs to treat rare kidney diseases, along with their recent initiatives?

Discover Below the Details on Top 5 Rare Kidney Disease Drug Developers

Let us dive deep into the details of the top 5 rare kidney disease drug developers. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Alexion Pharmaceuticals

Company Overview

Alexion, acquired by AstraZeneca in July 2021, is a global biopharmaceutical company that provides novel therapies, healthcare services and technologies for rare diseases across various therapeutic areas, including nephrology, hematology and neurology. Leveraging its 30 years of experience in research and development of therapeutics for rare diseases, Alexion delivers life-changing medicines to patients in over 50 countries.

The company has built a robust pipeline for addressing the unmet needs in rare kidney diseases. Notably, Alexion’s pipeline currently includes two blockbuster drugs Soliris (Eculizumab) and Ultomiris (Ravulizumab) for treating Atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).

Rare Kidney Disease Indications Targeted

The section provides information on the various types of rare kidney diseases targeted by Alexion’s drug portfolio:

Atypical Hemolytic Uremic Syndrome
Immunoglobulin A Nephropathy
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary Membranous Nephropathy

Recent Developments

In June 2026, the company received Priority Review Designation by the USFDA for its drug candidate Ultomiris (Ravulizumab), indicated for the treatment of Immunoglobulin A Nephropathy.

In April 2026, the company appointed Suhruth Dantu as Associate Director for Artificial Intelligence at Rare Disease Unit.

To know more about the recent initiatives of Alexion and other rare kidney disease drug developers, access full report.

2. Jiangsu Hengrui Pharmaceuticals

Company Overview

Jiangsu Hengrui Pharmaceuticals is an innovative pharmaceutical company specializing in the research, development, manufacturing and commercialization of novel drugs, generic drugs and over-the-counter products. The company focuses on various therapeutic areas, such as oncology, anesthesiology, cardiovascular diseases and metabolic disorders.

It is worth noting that the company has always prioritized scientific and technological innovation as its primary development strategy and has continued to increase its R&D investment. To date, Hengrui has invested more than RMB 50 billion in R&D, taking a lead in China's pharmaceutical industry.

Hengrui is actively developing therapeutics for treating major chronic diseases, including kidney diseases. The firm’s pipeline includes five drugs that are being evaluated at different clinical stages of development for treating rare kidney diseases.

Rare Kidney Disease Indications Targeted

The section provides information on the various types of rare kidney diseases targeted by Jiangsu Hengrui Pharmaceuticals’ drug portfolio:

Immunoglobulin A Nephropathy
Lupus Nephritis
Primary Membranous Nephropathy

Recent Developments

In April 2026, the company made key appointments to strengthen its leadership team, some of which include, the appointment of Feng Ji as the chief operating officer of Hengrui and the appointment of Zhu Guoxin as the senior vice president of Hengrui.

In March 2026, the company attended 11th BIOCHINA, to showcase its robust pipeline across oncology, diabetes and cardiovascular diseases among other disease areas, held at Suzhou International Expo Center Jiangsu Province, China.

To know more about the recent initiatives of Jiangsu Hengrui Pharmaceutical and other rare kidney disease drug developers, access full report.

3. Novartis

Company Overview

Novartis is a healthcare company headquartered in Switzerland that focuses on the discovery, development, manufacturing and marketing of innovative medicines. Notably, the firm specializes in the development of novel medicines across various therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology.

The firm leverages innovative technologies and strategies to produce high-value medicines that have consistently improved the patient’s quality of life over the past two decades. Moreover, the company is investing in R&D, with significant resources dedicated to the Novartis Institutes for BioMedical Research (NIBR) and the Global Drug Development (GDD) organization. These organizations are focused on discovering new medicines and conducting clinical trials to ensure regulatory approval. It is important to mention that Novartis operates across more than 30 production sites globally and manufactured over 20 billion treatments in 2025.

Rare Kidney Disease Indications Targeted

The section provides information on the various types of rare kidney diseases targeted by Novartis’ drug portfolio:

Immunoglobulin A Nephropathy
Lupus Nephritis
Complement 3 Glomerulopathy
Atypical Hemolytic Uremic Syndrome
Immune Complex-Mediated Membranoproliferative Glomerulonephritis

Recent Developments

In May 2026, the company announced the presentation of data from its kidney portfolio at the European Renal Association (ERA) Congress in Glassglow, to be held in Scotland, UK from 3-6 June.

In March 2026, the company announced a four-year collaboration with Helmholtz Munich for advancing kidney disease research. The collaboration aims to use Artificial Intelligence to predict how therapeutic interventions may restore diseased kidneys towards a healthier state by modeling treatment induced changes.

To know more about the recent initiatives of Novartis and other rare kidney disease drug developers, access full report.

4. Roche

Company Overview

Roche has over 125 years of experience in developing innovative solutions across a myriad of indications. The firm is dedicated towards offering personalized healthcare, leveraging its pharmaceutical and diagnostic capabilities.

It is worth noting that Roche is actively involved in addressing unmet needs in various kidney and kidney-related diseases. Further, the company is actively seeking partnerships and collaborations opportunities to enhance its access to healthcare and develop innovative medical solutions to address the unmet need in patient care.

Rare Kidney Disease Indications Targeted

The section provides information on the various types of rare kidney diseases targeted by Roche’s drug portfolio:

Lupus Nephritis
Pediatric Nephrotic Syndrome / Childhood Idiopathic Nephrotic Syndrome
Primary Membranous Nephropathy
Atypical Hemolytic Uremic Syndrome

Recent Developments

In February 2026, on the occasion of Rare Disease Day, the company presented its commitment towards developing innovative medicines for rare conditions, aligning with EURODIS and Genetic Alliance UK.

In the same month, the company appointed Mark Dawson as the new head of Roche Pharma Research and Early Development, Dawson will also be part of Enlarged Corporative Executive Committee.

To know more about the recent initiatives of Roche and other rare kidney disease drug developers, access full report.

5. Vertex Pharmaceuticals

Company Overview

Vertex Pharmaceuticals is a US-based biotechnology company focused on developing transformative medicines for severe diseases. The company has a robust pipeline of several molecules such as small molecules, mRNA, cell and gene therapies, along with various ongoing clinical and research programs.

Further, Vertex has four drugs under development targeting various indications of rare kidney diseases. It is interesting to note that the company has been recognized on Science magazine's Top Employers list for 13 consecutive years and is also named as one of the Fortune’s 100 Best Companies to Work For. Additionally, the company has research and development sites and commercial offices across various regions, including North America, Europe, Latin America and Australia.

Rare Kidney Disease Indications Targeted

The section provides information on the various types of rare kidney diseases targeted by Vertex Pharmaceuticals’ drug portfolio:

Immunoglobulin A Nephropathy
Focal Segmental Glomerulosclerosis
Primary Membranous Nephropathy
Autosomal Dominant Polycystic Kidney Disease
APOL1-mediated kidney disease

Recent Developments

In August 2026, the company announced its plans to participate in the 6th Annual Rare and Genetic Kidney Disease Drug Development Summit, to be held in Boston, Massachusetts.

In May 2026, the company was rewarded with 2026 Kidney Biotech Innovation Award from the National Kidney Foundation at the 2026 Spring Clinical Meeting, held in New Orleans. This award was granted for the company’s strategy and leadership in redefining kidney disease treatment though the development of innovative disease-modifying therapies.

To know more about the recent initiatives of Vertex Pharmaceuticals and other rare kidney disease drug developers, access full report.

What About Other Rare Kidney Disease Drug Developers Around the World?

The above article features the top rare kidney disease drug developers selected from a pool of nearly 95 manufacturers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources